All In Biotech

Drug Trial Radar · NCT03768505

Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

A Multicenter, Open Label Single-Arm, Phase 2 Study of Zandelisib (ME-401) in Subjects With Follicular Lymphoma and Marginal Zone Lymphoma After Failure of Two or More Prior Systemic Therapies (The TIDAL Study)

Last checked: Nov 19, 2026Latest source record: Dec 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

169

Actual

Start

Jun 25, 2019

Primary completion

Mar 24, 2023

Study completion Mar 24, 2023

Sponsor

Lead sponsor
MEI Pharma, Inc.Industry
Sponsor type
Industry
First posted
Dec 7, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is the study of the PI3Kδ inhibitor Zandelisib (ME-401) in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma after failure of at least 2 prior lines of systemic therapy

Conditions

  • Follicular Lymphoma (FL)
  • Non Hodgkin Lymphoma
  • Marginal Zone Lymphoma

Interventions

  • Zandelisib (ME-401)Drug

    Zandelisib (ME-401) 60 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) of ME-401 in Relapsed or Refractory FL or MZLTime frame: 3 years 9 months

Locations

115 sites in 14 countries. Site status is shown where the registry gives one.

  • Oncology Institute of Hope and Innovation

    Tucson, Arizona

  • Pacific Cancer Medical Center, Inc.

    Anaheim, California

  • Tower Hematology Oncology

    Beverly Hills, California

  • The Oncology Institute of Hope and Innovation

    Downey, California

  • Sharp Memorial Hospital

    San Diego, California

  • H. Lee Moffit Cancer Center

    Tampa, Florida

  • Cleveland Clinic-Florida

    Weston, Florida

  • Rush University Medical Center

    Chicago, Illinois

  • Advocate Health & Hospitals Corporation

    Niles, Illinois

  • Investigative Clinical Research of Indiana LLC

    Indianapolis, Indiana

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan Medical School

    Ann Arbor, Michigan

  • St. Vincent Frontier Cancer Center

    Billings, Montana

  • The Oncology Institute of Hope and Innovation

    Henderson, Nevada

  • Memorial Sloan Kettering

    Basking Ridge, New Jersey

  • Memorial Sloan Kettering

    Middletown, New Jersey

  • Memorial Sloan Kettering

    Montvale, New Jersey

  • San Juan Oncology

    Farmington, New Mexico

  • Memorial Sloan Kettering

    Commack, New York

  • Memorial Sloan Kettering

    Harrison, New York

  • Clinical Research Alliance

    Lake Success, New York

  • Memorial Sloan Kettering

    New York, New York

  • Stony Brook University

    Stony Brook, New York

  • Memorial Sloan Kettering

    Uniondale, New York

  • Duke Cancer Center

    Durham, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • Vanderbilt University

    Nashville, Tennessee

  • Renovatio Clinical

    Houston, Texas

  • Swedish Cancer Institute

    Edmonds, Washington

  • Swedish Cancer Institute

    Seattle, Washington

  • Medical Oncology Associates PS

    Spokane, Washington

  • University of Wisconsin Carbone Cancer Center

    Madison, Wisconsin

  • Marshfield Medical Center

    Marshfield, Wisconsin

  • Liverpool Hospital

    Sydney, Australia

  • Peninsula and South Eastern Haematology and Oncology Group

    Frankston, Victoria, Australia

  • The Perth Blood Institute

    West Perth, Western Australia, Australia

  • Kepler Universitatsklinikum GmBH

    Linz, Austria

  • Medical University of Vienna

    Vienna, Austria

  • AZ Sint-Jan Brugge-Oostende

    Bruges, Belgium

Showing 40 of 115 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.